I don't believe Jason would say that. It would ruin his credibility. He has a price target for AMBS at .20 cents by year end. He has said LymPro's revenue potential under CLIA is "several hundred million."

One million for 2015 would be a total failure of Lympro. He is not saying that. He is saying now is a good time to buy ;AMBS. Something doesn't add up.